Literature DB >> 22925027

Human papillomavirus infection and the risk of cervical cancer in Japan.

Koji Matsumoto1, Hiroyuki Yoshikawa.   

Abstract

Infection with a high-risk human papillomavirus (HPV) is established as a major risk factor for cervical cancer. In Japan, eight HPV genotypes (16, 18, 31, 33, 35, 45, 52 and 58) confer a much higher risk of cervical cancer and its immediate premalignant lesions (cervical intraepithelial neoplasia grade 3 [CIN 3]) than do other high-risk and the low-risk HPV types. However, only a small fraction of infected women develop CIN 3 or invasive cervical cancer, suggesting the involvement of additional cofactors in cervical carcinogenesis. A multicenter prospective cohort study of Japanese women with low-grade cervical abnormalities has demonstrated that tobacco smoking is significantly associated with an increased risk of persistent low-grade cervical lesions, while the presence of human leukocyte antigen Class II DRB1*1302 protects against progression to CIN 3. Understanding the epidemiology of HPV infections and cervical cancer may improve prevention and lead to novel clinical management strategies for cervical precursor lesions. Viral and host factors that affect the risk of cervical cancer are discussed in this review.
© 2012 The Authors. Journal of Obstetrics and Gynaecology Research © 2012 Japan Society of Obstetrics and Gynecology.

Entities:  

Mesh:

Year:  2012        PMID: 22925027     DOI: 10.1111/j.1447-0756.2012.01977.x

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  2 in total

1.  Association of HLA-DRB1, HLA-DQB1 Polymorphisms with HPV 16 E6 Variants among Young Cervical Cancer Patients in China.

Authors:  Yan Hu; Jin-Ze Wu; Hua Zhu; Sheng-Hui Zhang; Yan-Ying Zhu; Yi-Yao Wu; Ci-Xia Shuai
Journal:  J Cancer       Date:  2017-07-22       Impact factor: 4.207

2.  Cervical cancer screening rates before and after the Great East Japan Earthquake in the Miyagi Prefecture, Japan.

Authors:  Yasuhiro Miki; Toru Tase; Hideki Tokunaga; Nobuo Yaegashi; Kiyoshi Ito
Journal:  PLoS One       Date:  2020-03-11       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.